Sernova Biotherapeutics Cell Pouch Bio-hybrid Organ to be Highlighted at Cell & Gene Meeting on the Med
Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) announced that its Cell Pouch Bio-hybrid Organ, in development as a functional cure for type 1 diabetes (T1D), will be featured at the 2025 Cell & Gene Meeting on the Med conference in Rome.
The presentation will be part of a panel discussion titled 'Diabetes – Cell and Tissue Therapy Approaches to Provide Durable Therapeutic Solutions' on April 16, 2025. Dr. Bernd Muehlenweg, Senior Vice President at Evotec and Non-Executive Director at Sernova, will present data from the Sernova-Evotec collaboration during the session.
Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) ha annunciato che il suo Cell Pouch Bio-ibrido Organ, in fase di sviluppo come cura funzionale per il diabete di tipo 1 (T1D), sarà presentato alla conferenza 2025 Cell & Gene Meeting on the Med a Roma.
La presentazione farà parte di una tavola rotonda intitolata 'Diabete – Approcci di terapia cellulare e tissutale per fornire soluzioni terapeutiche durature' il 16 aprile 2025. Il dott. Bernd Muehlenweg, Senior Vice President di Evotec e Direttore Non Esecutivo di Sernova, presenterà i dati della collaborazione Sernova-Evotec durante la sessione.
Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) anunció que su Cell Pouch Bio-hybrid Organ, en desarrollo como una cura funcional para la diabetes tipo 1 (T1D), será presentado en la conferencia 2025 Cell & Gene Meeting on the Med en Roma.
La presentación formará parte de una mesa redonda titulada 'Diabetes – Enfoques de terapia celular y tisular para ofrecer soluciones terapéuticas duraderas' el 16 de abril de 2025. El Dr. Bernd Muehlenweg, Vicepresidente Senior de Evotec y Director No Ejecutivo de Sernova, presentará datos de la colaboración Sernova-Evotec durante la sesión.
Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF)는 제1형 당뇨병(T1D)의 기능적 치료제로 개발 중인 Cell Pouch Bio-hybrid Organ이 2025년 로마에서 열리는 Cell & Gene Meeting on the Med 컨퍼런스에서 소개될 것이라고 발표했습니다.
이 발표는 2025년 4월 16일에 열리는 '당뇨병 – 지속 가능한 치료 솔루션을 위한 세포 및 조직 치료 접근법'이라는 제목의 패널 토론의 일부로 진행됩니다. Evotec의 수석 부사장이자 Sernova의 비상임 이사인 Dr. Bernd Muehlenweg가 Sernova-Evotec 협력의 데이터를 세션 중에 발표할 예정입니다.
Sernova Biotherapeutics (TSX : SVA) (OTCQB : SEOVF) a annoncé que son Cell Pouch Bio-hybrid Organ, en cours de développement comme traitement fonctionnel pour le diabète de type 1 (T1D), sera présenté lors de la conférence 2025 Cell & Gene Meeting on the Med à Rome.
La présentation fera partie d'une table ronde intitulée « Diabète – Approches de thérapie cellulaire et tissulaire pour offrir des solutions thérapeutiques durables » le 16 avril 2025. Le Dr Bernd Muehlenweg, vice-président senior chez Evotec et administrateur non exécutif chez Sernova, présentera les données de la collaboration Sernova-Evotec durant la session.
Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) gab bekannt, dass sein Cell Pouch Bio-hybrid Organ, das als funktionelle Heilung für Typ-1-Diabetes (T1D) entwickelt wird, auf der 2025 Cell & Gene Meeting on the Med Konferenz in Rom vorgestellt wird.
Die Präsentation ist Teil einer Podiumsdiskussion mit dem Titel 'Diabetes – Zell- und Gewebetherapieansätze für dauerhafte therapeutische Lösungen' am 16. April 2025. Dr. Bernd Muehlenweg, Senior Vice President bei Evotec und Non-Executive Director bei Sernova, wird während der Sitzung Daten aus der Zusammenarbeit zwischen Sernova und Evotec präsentieren.
- Strategic partnership with Evotec demonstrates collaborative progress in diabetes treatment development
- None.
LONDON, Ontario and BOSTON, April 15, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company, today announced that the Company’s Cell Pouch Bio-hybrid Organ in clinical development as a functional cure for type 1 diabetes (T1D) will be highlighted in a panel discussion titled Diabetes – Cell and Tissue Therapy Approaches to Provide Durable Therapeutic Solutions at the 2025 Cell & Gene Meeting on the Med conference in Rome, Italy on Wednesday, April 16, 2025.
Session Details
Science Slam: Diabetes – Cell and Tissue Therapy Approaches to Provide Durable Therapeutic Solutions; Wednesday, April 16, 2025, 1:45 – 2:45pm CET
Moderator: Eytan Abraham, Ph.D., Chief Commercial and Technology Officer, Minaris Regenerative Medicine
Speakers:
- Bernd Muehlenweg, Ph.D., Senior Vice President, Head of Global Business Development, Cell Therapy, Evotec; Non-Executive Director, Sernova
- Vlad Seitan, Ph.D., Chief Scientific Officer, Laverock Therapeutics
- Harald Stover, Ph.D., Founder and CEO, Allarta Life Science; Professor of Chemistry and Chemical Biology, McMaster University
“We are delighted to have the opportunity for Dr. Bernd Muehlenweg to present data from Sernova and Evotec at the Cell & Gene Meeting on the Med conference,” stated Jonathan Rigby, CEO and President of Sernova. “His presentation of our collaborative efforts recognizes the strength of our partnership with Evotec as well as the scientific community’s interest in our Cell Pouch Bio-hybrid Organ as a viable approach to providing a functional cure for patients living with type 1 diabetes.”
ABOUT SERNOVA BIOTHERAPEUTICS
Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet like clusters in collaboration with Evotec to create bio-hybrid organs to treat T1D. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on T1D and thyroid disorders.
FOR FURTHER INFORMATION, PLEASE CONTACT:
David Burke VP, Investor Relations (917) 751-5713 Email: David.Burke@sernova.com Website: https://sernova.com/
The TSX has not reviewed this news release and does not accept responsibility for the accuracy or adequacy of this news release.
FAQ
What will Sernova (SEOVF) present at the 2025 Cell & Gene Meeting on the Med conference?
When and where will Sernova's (SEOVF) presentation take place at the Cell & Gene Meeting?
Who will present Sernova's (SEOVF) diabetes treatment technology at the conference?
What is the focus of Sernova's (SEOVF) Cell Pouch Bio-hybrid Organ development?
